Affiliations: [a] Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil | [b] Department of Biology, Faculty of Philosophy, Sciences, and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil | [c] Technological Advances for Genomics and Clinics (TAGC), UMR, S 1090 INSERM Aix-Marseille Université, U928 Parc Scientifique de Luminy Case 928 163, Avenue de Luminy, 13288 Marseille Cedex 9, France
Correspondence:
[*]
Corresponding author: Elza Tiemi Sakamoto-Hojo, Department of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo; Av. Bandeirantes 3900, Zip Code: 14040-901, Ribeirão Preto, SP, Brazil. Tel.: +55 16 3315 3827; Fax: +55 16 3315 0222; E-mail:etshojo@usp.br
Abstract: BACKGROUND: Glioblastoma is considered to the most common and
malignant brain tumor in adults. Patients have a median survival of
approximately one year from diagnosis due to poor response to therapy. OBJECTIVE: We applied bioinformatics approaches to predict
transcription factors (TF) that are deregulated in glioblastoma in an
attempt to point out molecular targets for therapy. METHODS: Up-regulated genes in glioblastoma selected from public
microarray data were submitted to two TF association analyses. Thereafter,
the expression levels of TF obtained in the overlap of analyses were
assessed by RT-qPCR carried out in seven glioblastoma cell lines (T98, U251, U138, U87, U343, M059J, and M059K). RESULTS: E2F1 and E2F4 were highlighted in both TF analyses. However, only
E2F1 was confirmed as significantly up-regulated in all glioblastoma cell lines
in vitro. CONCLUSION: E2F1 is a potential common regulator of differentially
expressed genes in glioblastoma, despite the genetic heterogeneity of tumor cells.
